Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 4/20 | 0.42 |
| ▸ | CES1 | P23141 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 5/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31325309 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRTHRBCES2CES1 | |
| SCHEMBL264832 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRTHRBCES2CES1 | |
| SCHEMBL30906963 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRTHRBCES2CES1 | |
| SCHEMBL1117292 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRTHRBCES2CES1 | |
| SCHEMBL1117388 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRTHRBCES2CES1 | |
| SCHEMBL1117344 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRTHRBCES2CES1 | |
| SCHEMBL264639 | 1.00 | — | — | |
| SCHEMBL1117329 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRTHRBCES2CES1 | |
| SCHEMBL1117312 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRTHRBCES2CES1 | |
| SCHEMBL30906969 | 1.00 | ALDH1A1 (1.00) | ALDH1A1TSHRTHRBCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542277-B2 | Nitrated hydrocarbons, derivatives, and processes for their manufacture | ANGUS CHEMICAL COMPANY (US) | 2023-01-03 | — | — | US | claimed |
| US-20220170066-A1 | DIFFERENTIATION OF LYME DISEASE AND SOUTHERN TICK-ASSOCIATED RASH ILLNESS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2022-06-02 | — | — | US | claimed |
| US-11230728-B2 | Differentiation of lyme disease and southern tick-associated rash illness | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2022-01-25 | — | — | US | claimed |
| EP-3121162-B1 | PROCESS FOR PREPARING NITRATED HYDROCARBONS AND THEIR DERIVATIVES | ANGUS CHEMICAL (US) | 2021-05-26 | — | — | EP | claimed |
| US-20190315768-A1 | NITRATED HYDROCARBONS, DERIVATIVES, AND PROCESSES FOR THEIR MANUFACTURE | ADVANCION CORPORATION | 2019-10-17 | — | — | US | claimed |
| US-20180127435-A1 | NITRATED HYDROCARBONS, DERIVATIVES, AND PROCESSES FOR THEIR MANUFACTURE | ADVANCION CORPORATION | 2018-05-10 | — | — | US | claimed |
| EP-3121162-A1 | NITRATED HYDROCARBONS AND DERIVATIVES | ANGUS CHEMICAL COMPANY (US) | 2017-01-25 | — | — | EP | claimed |
| US-20160039843-A1 | NITRATED HYDROCARBONS, DERIVATIVES, AND PROCESSES FOR THEIR MANUFACTURE | ADVANCION CORPORATION | 2016-02-11 | — | — | US | claimed |
| CN-101998948-A | Nitrated hydrocarbons, derivatives and processes for their manufacture | DOW GLOBAL TECHNOLOGIES INCANGUS CHEMICAL COMPANY | 2011-03-30 | — | — | CN | claimed |
| EP-2280927-A1 | NITRATED HYDROCARBONS, DERIVATIVES, AND PROCESSES FOR THEIR MANUFACTURE | ANGUS CHEMICAL COMPANY (US) | 2011-02-09 | — | — | EP | claimed |
| US-20110028732-A1 | NITRATED HYDROCARBONS, DERIVATIVES, AND PROCESSES FOR THEIR MANUFACTURE | ANGUS CHEMICAL COMPANY (US) | 2011-02-03 | — | — | US | claimed |
| WO-2009129097-A1 | NITRATED HYDROCARBONS, DERIVATIVES, AND PROCESSES FOR THEIR MANUFACTURE | ANGUS CHEMICAL COMPANY (US) | 2009-10-22 | — | — | WO | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-3638678-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4186888-B1 | COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2025-11-26 | — | — | EP | disclosed |
| US-3993685-A | Process for the production of urethanes | ATLANTIC RICHFIELD COMPANY (US) | 1976-11-23 | — | — | US | disclosed |
| US-3989755-A | CATALYST COMPRISING SELENIUM METAL OR INORGANIC SALTS, AND A BASE | ATLANTIC RICHFIELD COMPANY (US) | 1976-11-02 | — | — | US | disclosed |
| US-3956360-A | REACTING HYDROXY COMPOUND WITH CARBON MONOXIDE AND AN ORGANIC COMPOUND | ATLANTIC RICHFIELD COMPANY (US) | 1976-05-11 | — | — | US | disclosed |
| US-3953488-A | Method for preparing aliphatic and cycloaliphatic isothiocyanates | OLIN CORPORATION (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127435-A1 | NITRATED HYDROCARBONS, DERIVATIVES, AND PROCESSES FOR THEIR MANUFACTURE | NOS2, NOS1, NOS3 | ALDH1A1 1410/4885TSHR 3019/4885THRB 2729/4885 |
| US-11542277-B2 | Nitrated hydrocarbons, derivatives, and processes for their manufacture | NOS2, NOS1, NOS3 | ALDH1A1 1410/4885TSHR 3019/4885THRB 2729/4885 |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | SIN3A, PLIN3, MSR1 | ALDH1A1 4755/4885TSHR 540/4885THRB 2128/4885 |
| US-20190315768-A1 | NITRATED HYDROCARBONS, DERIVATIVES, AND PROCESSES FOR THEIR MANUFACTURE | NOS2, NOS1, NOS3 | ALDH1A1 1410/4885TSHR 3019/4885THRB 2729/4885 |
| US-20110028732-A1 | NITRATED HYDROCARBONS, DERIVATIVES, AND PROCESSES FOR THEIR MANUFACTURE | NOS2, NOS1, NOS3 | ALDH1A1 1410/4885TSHR 3019/4885THRB 2729/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | ALDH1A1 568/4885TSHR 4804/4885THRB 3769/4885 |
| US-20160039843-A1 | NITRATED HYDROCARBONS, DERIVATIVES, AND PROCESSES FOR THEIR MANUFACTURE | NOS2, NOS1, NOS3 | ALDH1A1 1410/4885TSHR 3019/4885THRB 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.